154
Participants
Start Date
February 2, 2015
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2026
Pertuzumab
In general, patients will continue to receive 420 milligrams (mg) of pertuzumab administered as an intravenous infusion every 3 weeks following the guidance of the Parent protocol.
Trastuzumab
If trastuzumab intravenous infusions were given in combination with pertuzumab as part of the Parent study, patients will continue to receive treatment at the same dose, schedule and under the same administration guidelines which were in effect at the time of Parent study closure.
Other Combination Anti-Cancer Therapies
If other anti-cancer therapies were given in combination with pertuzumab as part of the Parent study, patients will receive all treatments at the same dose, schedule and under the same administration guidelines which were in effect at the time of Parent study closure.
Hospital Metropolitano (Sede Lindora-Santa Ana), San José
Instituto Nacional de Cancerologia, Distrito Federal
Asst Di Monza, Monza
Irccs Istituto Europeo Di Oncologia (IEO), Milan
Praxis für Ambulante Onkologie im Krankenhaus Jerusalem, Hamburg
Centre Georges Francois Leclerc, Dijon
Clinique Armoricaine Radiologie, Saint-Brieuc
Studienzentrum UnterEms;Onkologische Schwerpunktpraxis Leer, Leer
Hospital Universitario de Canarias, San Cristóbal de La Laguna
Hospital Universitario Marques de Valdecilla, Santander
Az. Osp. S. Orsola Malpighi, Bologna
AUSL ? IRCCS Santa Maria Nuova, Reggio Emilia
Hospital Universitari i Politecnic La Fe, Valencia
IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola, Meldola
Hospital de Basurto, Bilbao
Mun. Multifield Clin.Hosp.#4,Dept. of Chemotherapy, DSMU, Dnipropetrovsk
A.O. Universitaria Pisana, Pisa
Hämatologisch-Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus, Frankfurt am Main
Irccs Ist. Tumori Giovanni Paolo Ii, Bari
Centre Henri Becquerel, Rouen
State Oncology Regional Treatment-Diagnostic Center, Lviv
Praxis für Interdisziplinäre Onkologie und Hämatologie GbR, Freiburg im Breisgau
Centre Rene Huguenin, Saint-Cloud
Onkologische Praxis Neumarkt (Dr. med. Ekkehart Ladda), Neumarkt
Beijing Cancer Hospital, Beijing
Liaoning cancer Hospital & Institute, Shenyang
The First Hospital of Jilin University, Changchun
Harbin Medical University Cancer Hospital, Harbin
Fudan University Shanghai Cancer Center, Shanghai
Fudan University Shanghai Cancer Center, Shanghai
Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University), Nanjing
Kursk Regional Clinical Oncology Dispensary, Kursk
Zhejiang Cancer Hospital, Hangzhou
SBI of Healthcare Samara Regional Clinical Oncology Dispensary, Samara
West China Hospital, Sichuan University, Chengdu
Santa Casa de Misericordia de Porto Alegre, Porto Alegre
Hospital Amaral Carvalho, Jaú
Instituto do Cancer do Estado de Sao Paulo - ICESP, São Paulo
Hospital Sírio-Libanês, São Paulo
Hospital Perola Byington, São Paulo
Núcleo de Pesquisa São Camilo, São Paulo
Instituto de Oncologia de Sorocaba - CEPOS, Sorocaba
Instituto Nacional de Cancer - INCa, Rio de Janeiro
National Cancer Center Hospital East, Chiba
Gifu University Hospital, Gifu
Saitama Cancer Center, Saitama
Iem-Fucam, D.F.
CENEIT Oncologicos, Mexico City
Hospital Nacional Carlos Alberto Seguin Escobedo-Essalud, Arequipa
Clinica Anglo Americana - Centro de Investigacion Oncologia CAA, Lima
Clinica Internacional, Sede San Borja, Lima
Samodzielny Publiczny Kliniczny Nr 1 W Lublinie, Lublin
IPO de Coimbra, Coimbra
Hospital da Luz, Lisbon
Hospital de Santa Maria, Lisbon
IPO do Porto, Porto
Seoul National University Hospital, Seoul
Severance Hospital, Yonsei University Health System, Seoul
Asan Medical Center, Seoul
ICO L'Hospitalet, L'Hospitalet de Llobregat
Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Barcelona
Hoffmann-La Roche
INDUSTRY